Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | CHAARTED2: CTC and AR-V7 analysis of abiraterone ± cabazitaxel in mCRPC

Christos Kyriakopoulos • 14 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer Abiraterone Cabazitaxel Docetaxel
CHAARTED2

Christos Kyriakopoulos, MD, University of Wisconsin, Madison, WI, discusses the prognostic and predictive impact of circulating tumor cells (CTC) and AR-V7 in the CHAARTED2 trial (NCT03419234) of abiraterone with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel. Baseline detection of CTC and AR-V7 correlated with poorer progression-free survival. Conversion to negative status at cycle 5, day 1 was associated with better outcomes. While AR-V7 positivity indicated potential benefit from combination therapy, statistical significance was not reached. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Christos Kyriakopoulos

Treatment options for patients with metastatic castration-resistant prostate cancer
1:10
Treatment options for patients with metastatic castration-resistant prostate cancer
Christos Kyriakopoulos • 2 Jun 2024
CHAARTED2: cabazitaxel plus abiraterone vs. abiraterone alone for metastatic CRPC
2:07
CHAARTED2: cabazitaxel plus abiraterone vs. abiraterone alone for metastatic CRPC
Christos Kyriakopoulos • 2 Jun 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals